In line with the progress made in Retevmo’s reimbursement review process, its competitor Gavreto was also found to have started its reimbursement process in Korea.

According to industry sources, Roche Korea submitted an application for the reimbursement of its RET (Rearranged during transfection) gene fusion targeted therapy Gavreto (pralsetinib).

With the reimbursement agenda for Lilly Korea’s Retevmo (selpercatinib) passing the Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Committee (CDDC) meeting earlier this month, the industry’s eyes are on the reimbursement progress of the two drugs.

At the meeting, the CDDC set reimbursement stan